Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991941 | 0.92 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9AKLK7MAPT | |
| SCHEMBL21992637 | 0.90 | PPARA (0.40) | L3MBTL1KLK7PPARGPPARALMNA | |
| SCHEMBL21991912 | 0.89 | L3MBTL1 (0.44) | L3MBTL1NPC1RAB9AKLK7MAPT | |
| SCHEMBL21991315 | 0.89 | HPGD (0.40) | L3MBTL1NPC1RAB9AMAPTPPARG | |
| SCHEMBL21991318 | 0.87 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9AKLK7MAPT | |
| SCHEMBL21991966 | 0.87 | PPARG (0.38) | PPARGPPARA | |
| SCHEMBL21991904 | 0.86 | MAOB (0.44) | L3MBTL1NPC1RAB9APPARGPPARA | |
| SCHEMBL21991952 | 0.84 | L3MBTL1 (0.53) | L3MBTL1NPC1RAB9AMAPTPPARG | |
| SCHEMBL21992647 | 0.81 | PPARA (0.41) | MAPTPPARGPPARAKMT2AMEN1 | |
| SCHEMBL21991879 | 0.80 | MTNR1A (0.43) | KLK7MAPTPPARGPPARALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885NPC1 233/4885RAB9A 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.